Could vitamin D supplements be a new therapy for heart failure? Possible pathogenic mechanisms from data of

Andrea Dalbeni1, Pietro Delva, Pietro Minuz

  • 1Section of Internal Medicine, Department of Biomedical and Surgical Science, University of Verona, Policlinico "GB Rossi", P.le Scuro 1, 37134, Verona, Italy, andrea.dalbeni@ospedaleuniverona.it.

Insights

Vitamin D deficiency is common in heart failure (HF) patients and linked to poor outcomes. More research is needed to determine if vitamin D supplements improve survival in chronic HF.

Area of Science:

  • Cardiology
  • Endocrinology
  • Nutritional Science

Background:

  • Vitamin D deficiency is prevalent in patients with chronic heart failure (HF).
  • Low vitamin D levels are associated with adverse outcomes in HF, particularly in the elderly, obese, and individuals with darker skin.
  • Experimental data in mice show vitamin D receptor deficiency leads to myocardial hypertrophy and dysfunction.

Purpose of the Study:

  • To investigate the role of vitamin D deficiency in the pathogenesis of chronic heart failure (HF).
  • To determine if vitamin D supplementation improves survival in patients with chronic HF.

Main Methods:

  • Review of epidemiological data linking vitamin D levels to HF outcomes.
  • Analysis of experimental studies on vitamin D receptor knockout mice.
  • Assessment of existing interventional studies on vitamin D supplementation in HF.

Main Results:

  • Vitamin D deficiency is common in HF patients and associated with adverse outcomes.
  • Experimental models support a role for vitamin D in myocardial health.
  • Data from interventional studies are limited and conflicting.

Conclusions:

  • Vitamin D deficiency may contribute to heart failure development and progression.
  • The efficacy of vitamin D supplementation for improving survival in chronic HF remains uncertain.
  • Further rigorous research, including interventional trials, is essential to clarify the role of vitamin D in HF management.

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
631
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
621
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.5K
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
788
Role of Skin in Vitamin D Synthesis01:23

Role of Skin in Vitamin D Synthesis

The skin plays a crucial role in the synthesis of vitamin D, a vital nutrient for various physiological processes in the body. Vitamin D is unique because it can be synthesized in the skin through a series of chemical reactions triggered by exposure to ultraviolet B (UVB) radiation from sunlight.
The solar UV B rays (290-315 nm) are absorbed by the skin, and 7-dehydrocholesterol (provitamin D3) photolyzes it to previtamin D3, which undergoes a rapid transformation to vitamin...
8.0K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.9K